These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 18494752

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
    Al-Badriyeh D, Liew D, Stewart K, Kong DC.
    J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
    Wingard JR, Leather HL, Wood CA, Gerth WC, Lupinacci RJ, Berger ML, Mansley EC.
    Am J Health Syst Pharm; 2007 Mar 15; 64(6):637-43. PubMed ID: 17353573
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.
    Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP.
    Eur J Haematol; 2008 Dec 15; 81(6):467-74. PubMed ID: 18754857
    [Abstract] [Full Text] [Related]

  • 16. Economic Comparison of an Empirical Versus Diagnostic-Driven Strategy for Treating Invasive Fungal Disease in Immunocompromised Patients.
    Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J.
    Clin Ther; 2015 Jun 01; 37(6):1317-1328.e2. PubMed ID: 25891805
    [Abstract] [Full Text] [Related]

  • 17. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP.
    Pharmacotherapy; 2007 Jul 01; 27(7):970-9. PubMed ID: 17594202
    [Abstract] [Full Text] [Related]

  • 18. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
    Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, Arndt CA, Schuster M, Seibel N, Yeldandi V, Tong KB.
    J Clin Oncol; 2000 Jun 01; 18(12):2476-83. PubMed ID: 10856108
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
    Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A.
    Value Health; 2006 Jun 01; 9(1):12-23. PubMed ID: 16441520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.